Home Guides Tirzepatide vs Semaglutide 2026
Tirzepatide vs Semaglutide 2026: The Head-to-Head, the Cost Gap, and Who Should Pick Which
In the only large randomized head-to-head, SURMOUNT-5, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks — roughly 47% more relative loss. Semaglutide re…
In the only large randomized head-to-head, SURMOUNT-5, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks — roughly 47% more relative loss. Semaglutide retains the stronger cardiovascular outcomes label from SELECT and costs less in compounded form.
On this page
The efficacy question is settled
SURMOUNT-5 randomized 751 adults to maximum tolerated tirzepatide or maximum tolerated semaglutide for 72 weeks. Tirzepatide won on every weight endpoint: 20.2% vs 13.7% mean loss, 64.6% vs 40.1% achieving at least 15% loss, and 18.4 cm vs 13.0 cm of waist reduction.
The mechanistic explanation is that tirzepatide agonises both the GIP and GLP-1 receptors while semaglutide acts on GLP-1 alone. GIP agonism adds central appetite signaling and adipose insulin sensitisation, and may blunt nausea enough to allow greater effective exposure.
Where semaglutide still wins
SELECT showed a 20% reduction in major adverse cardiovascular events over nearly four years in 17,604 people with obesity and established cardiovascular disease — the first trial to prove hard outcome benefit for a weight-management drug. Tirzepatide's SURPASS-CVOT demonstrated non-inferiority to dulaglutide with a favorable all-cause mortality signal, which narrows but does not fully close that gap.
Semaglutide also has more years of real-world exposure, broader insurance formulary presence, and an oral option. And in compounded form it is consistently cheaper — often $69–$149 per month against $99–$249 for tirzepatide.
The tolerability trade
Discontinuation for adverse events in SURMOUNT-5 was 6.1% on tirzepatide and 8.0% on semaglutide. In practice, semaglutide skews toward more nausea and tirzepatide toward more constipation. Neither difference is large enough to drive the decision on its own.
How to actually choose
Pick tirzepatide if maximum weight loss is the goal, if you have plateaued on semaglutide, or if you have moderate-to-severe obstructive sleep apnea with obesity, where Zepbound carries a specific FDA indication.
Pick semaglutide if you have established cardiovascular disease and want the drug with the specific outcomes label, if your insurance covers Wegovy or Ozempic but not Zepbound, or if the compounded price gap is the difference between staying on treatment for a year and quitting at month four.
The drug you can afford for twelve months beats the drug you abandon at month three. Time on treatment predicts results more reliably than which molecule you started.
Common questions
Do I need a prescription for tirzepatide?
Yes, always — for brand and compounded alike. Any seller shipping tirzepatide without a prescription from a licensed prescriber is operating illegally, and the product should not be considered pharmaceutical grade.
Can I switch from semaglutide to tirzepatide without starting over?
You restart at 2.5 mg tirzepatide regardless of your semaglutide dose, because there is no equivalence between the molecules. Most switchers find re-titration far easier than a first start — roughly 13% report GI symptoms — because GLP-1 receptor adaptation carries over. Take the first tirzepatide dose about seven days after your last semaglutide injection.
Why is some tirzepatide advertised under $100 a month?
Usually one of four reasons: it is the 2.5 mg starter-tier price only, it is an introductory rate that reverts, there is a separate membership fee, or the product is not from a licensed US pharmacy. Ask what you will pay at 10 mg before you enrol.
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy compounds for an identified individual patient with a prescription and is licensed by a state board of pharmacy. A 503B outsourcing facility registers with FDA, may compound in bulk without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. Most compounded tirzepatide now flows through the 503A pathway.
People also ask about tirzepatide vs semaglutide
What is tirzepatide vs semaglutide?
Tirzepatide vs semaglutide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide vs semaglutide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide vs semaglutide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide vs semaglutide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.